Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001172661-25-002361
Filing Date
2025-05-15
Accepted
2025-05-15 16:20:55
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8696
  Complete submission text file 0001172661-25-002361.txt   10426
Mailing Address 77 WEST WACKER DRIVE 7TH FLOOR CHICAGO IL 60601
Business Address 77 WEST WACKER DRIVE 7TH FLOOR CHICAGO IL 60601 312-899-7902
Alyeska Investment Group, L.P. (Filed by) CIK: 0001453072 (see all company filings)

EIN.: 261919051 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Subject) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91770 | Film No.: 25953669
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)